Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

302
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
302
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

274
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
274
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

265
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
265
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

225
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
225
Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

4.9K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
4.9K
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

5.1K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AI-enhanced multimodal spectroscopy for monitoring volatile organic compounds in pharmaceutical wastewater.

Water research·2025
Same author

A Real-Time Cell Image Segmentation Method Based on Multi-Scale Feature Fusion.

Bioengineering (Basel, Switzerland)·2025
Same author

Comparative transcriptomic analysis reveals bioluminescence-related genes in firely Pyrocoelia pectoralis.

Genomics·2025
Same author

Discoidin, CUB and LCCL domain containing 2 modulates angiogenesis by inhibiting VEGF receptor 2 endocytosis in endothelial cells.

Journal of molecular medicine (Berlin, Germany)·2025
Same author

Direct Production of Cyclohexanones from Lignin via Chlorine-Mediated Catalytic Hydroprocessing.

Angewandte Chemie (International ed. in English)·2025
Same author

BCL-2/BCL-X<sub>L</sub> dual inhibition triggers Gasdermin D-mediated pyroptosis in mantle cell lymphoma.

Cancer letters·2025

Related Experiment Video

Updated: Feb 5, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K

Dose Finding in Late-Phase Drug Development.

Lei Nie1, Kyung Y Lee1, Nicole Verdun2

  • 11 Office of Biostatistics/CDER/FDA, Silver Spring, MD, USA.

Therapeutic Innovation & Regulatory Science
|September 19, 2018
PubMed
Summary
This summary is machine-generated.

This study introduces a framework for Phase IV trials to optimize drug regimens when efficacy is met but toxicity concerns arise. It uses statistical modeling to predict optimal doses, ensuring better treatment outcomes and patient safety.

Keywords:
Bayesian designdose-responsedose-toxicitymarginal structure model

More Related Videos

Robotic Production of Cancer Cell Spheroids with an Aqueous Two-phase System for Drug Testing
09:58

Robotic Production of Cancer Cell Spheroids with an Aqueous Two-phase System for Drug Testing

Published on: April 23, 2015

9.5K
Primary Neuronal Cultures from the Brains of Late Stage Drosophila Pupae
15:12

Primary Neuronal Cultures from the Brains of Late Stage Drosophila Pupae

Published on: May 28, 2007

15.7K

Related Experiment Videos

Last Updated: Feb 5, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K
Robotic Production of Cancer Cell Spheroids with an Aqueous Two-phase System for Drug Testing
09:58

Robotic Production of Cancer Cell Spheroids with an Aqueous Two-phase System for Drug Testing

Published on: April 23, 2015

9.5K
Primary Neuronal Cultures from the Brains of Late Stage Drosophila Pupae
15:12

Primary Neuronal Cultures from the Brains of Late Stage Drosophila Pupae

Published on: May 28, 2007

15.7K

Area of Science:

  • Pharmacology
  • Clinical Trial Design
  • Biostatistics

Background:

  • Drugs may exhibit late-onset toxicities not detected in early trials, leading to concerns despite meeting efficacy objectives.
  • Unacceptable toxicity profiles can compromise drug development and post-marketing surveillance, necessitating advanced trial designs.

Purpose of the Study:

  • To propose a general framework for designing Phase IV trials to optimize drug regimens.
  • To address situations where drug efficacy is confirmed but toxicity concerns persist.
  • To integrate existing data and statistical modeling for dose optimization in later-phase trials.

Main Methods:

  • Utilizing existing data to explore dose-response and dose-toxicity relationships.
  • Developing statistical models to predict efficacy metrics and safety parameters for various doses.
  • Comparing design options for Phase IV clinical trials that incorporate exploratory analysis findings.

Main Results:

  • A framework is proposed for Phase IV trial design focused on optimizing treatment regimens.
  • Statistical modeling can predict potential efficacy and safety outcomes at different doses.
  • Incorporating exploratory analysis predictions aids in designing effective dose-finding trials.

Conclusions:

  • The proposed framework provides a systematic approach to optimize drug regimens in Phase IV trials.
  • Statistical modeling of dose-response and dose-toxicity relationships is crucial for informed trial design.
  • Phase IV trials can be effectively designed to find optimal doses, fulfilling post-marketing requirements and enhancing patient safety.